

Resource Summary Report

Generated by [kravitz2](#) on Sep 5, 2026

Spark Blue(TM) 550 anti-human CD14

RRID:AB_2832724

Type: Antibody

Proper Citation

BioLegend Cat# 367148, RRID:AB_2832724

Antibody Information

URL: http://antibodyregistry.org/AB_2832724

Proper Citation: BioLegend Cat# 367148, RRID:AB_2832724

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Spark Blue(TM) 550 anti-human CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: Clone 63D3

Antibody ID: AB_2832724

Vendor: BioLegend

Catalog Number: 367148

Alternative Catalog Numbers: 367147

Record Creation Time: 20231110T032404+0000

Record Last Update: 20260829T091754+0000

Ratings and Alerts

No rating or validation information has been found for Spark Blue(TM) 550 anti-human CD14.

No alerts have been found for Spark Blue(TM) 550 anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Marciello I, et al. (2025) Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry. *STAR protocols*, 6(2), 103775.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. *Cancer cell*.

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. *The Journal of experimental medicine*, 222(7).

de Homdedeu M, et al. (2023) *Mycobacterium manresensis* induces trained immunity in vitro. *iScience*, 26(6), 106873.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Szymula A, et al. (2023) Macrophages drive KSHV B cell latency. *Cell reports*, 42(7), 112767.

Haubner S, et al. (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. *Cancer cell*, 41(11), 1871.

Lozano-Rodríguez R, et al. (2022) Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. *Cell reports*, 38(2), 110235.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.

Mulder K, et al. (2021) Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. *Immunity*, 54(8), 1883.